Prevalence of immunology testing in patients treated with alglucosidase alfa with significant hypersensitivity/anaphylactic reactions (ALGMYC07390)

First published: 03/08/2015 Last updated: 25/06/2024



Study status



Administrative details

EU PAS number EUPAS10526		
LOFAS10320		
Study ID		
37523		
DARWIN EU® study		
No		
Study countries		
France		
Germany		

Research institutions and networks

Institutions

Sanofi

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Team Transparency contact-us@sanofi.com

Study contact

contact-us@sanofi.com

Primary lead investigator

Stéphanie Tcherny-Lessenot

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 23/03/2015

Actual: 23/03/2015

Study start date

Planned: 31/12/2015 Actual: 01/07/2016

Data analysis start date

Planned: 30/09/2016 Actual: 30/09/2016

Date of interim report, if expected

Planned: 31/12/2016 Actual: 23/12/2016

Date of final study report

Planned: 31/08/2019 Actual: 12/12/2019

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Genzyme Europe B.V., The Netherlands

Study protocol

rdct-ALGMYC07390_study protocol_V3_final 14dec2015_approved-PDFA.pdf (320.63 KB)

Regulatory

was the study required by a requiatory b	the study required by a regulatory body?	•
--	--	---

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Other study registration identification numbers and links

ALGMYC07390

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Data collection methods:

Secondary use of data

Main study objective:

This study aims to determine the prevalence of patients treated with alglucosidase alfa with significant hypersensitivity/anaphylactic reactions who undergo immunology testing. The difference in prevalence of testing between the two periods of 3 years before and after the implementation of the revised SIP (version 8.2) will be assessed as a measure of effectiveness of risk minimization measures.

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Name of medicine

MYOZYME

Study drug International non-proprietary name (INN) or common name

ALGLUCOSIDASE ALFA

Anatomical Therapeutic Chemical (ATC) code

(A16AB07) alglucosidase alfa alglucosidase alfa

Medical condition to be studied

Population studied

Short description of the study population

The population included all patients treated with alglucosidase alfa with a spontaneously reported significant hypersensitivity/anaphylactic reaction to the Sanofi Genzyme Pharmacovigilance adverse event database during the study period within European countries in which the revised SIP had been distributed by March 31, 2016.

Age groups

Infants and toddlers (28 days - 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

1

Study design details

Data analysis plan

The primary analysis population will be patients from Europe. The analyses will be descriptive and will be made on all patients available in the databases at time of each analysis. The prevalence of testing will be provided for each period

(3-year period before and 3-year period after implementation of the revised SIP). The results will be displayed by 3-year period before and after the implementation of revised SIP and by country in Europe when appropriate.

Documents

Study results

rdct-alglucosidase-alfa-PASS-immunology-testing_finalreport_abstract_FINAL 08
June 2020-PDFA.pdf (159.55 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other

- Sanofi Genzyme Pharmacovigilance adverse event database
- Genzyme Clinical Specialty Laboratory database

Data sources (types)

Other

Data sources (types), other

Routine performance of immunology testing since treatment start

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No